FDA Email Spying: Crisis Experts Say Agency Needs To Tell Its Story Better

OIG has launched an investigation of FDA’s pre-market review process after the Office of Special Counsel concluded that two devices approved over the objection of FDA scientists likely pose imminent risk to public.